Remarkable progress has been made in the development of biomarker-driven targeted
therapies for patients with multiple cancer types, including melanoma, breast and lung …

Background Colorectal cancer (CRC) is still a leading cause of cancer-related deaths in the
United States and worldwide, despite recent improvements in cancer management. CRC …

Background Recognition of rare molecular subgroups is a challenge for precision oncology
and may lead to tissue-agnostic approval of targeted agents. Here we aimed to …

Colorectal cancer (CRC) is the second most frequent cause of direct cancer death
worldwide. The study of the molecular state of oncogenes has predictive and prognostic …

Vemurafenib is a B-Raf V600E inhibitor that exerts significant inhibitory effects in melanoma
but not in colon cancer, and the mechanism of vemurafenib resistance remains unclear. In …

The use of targeted agents in the treatment of metastatic colorectal cancer (CRC) has
improved patient outcomes. Anti-epidermal growth factor receptor (anti-EGFR) agents …

Temozolomide is an oral alkylating agent used for treating several cancers including
glioblastoma and melanoma. Promising, albeit limited, activity and efficacy of temozolomide …

Cetuximab (brand name Erbitux) is a monoclonal antibody used in the treatment of
metastatic colorectal cancer (mCRC) and cancer of the head and neck. Cetuximab is an …

Purpose Careful patient selection plays a crucial role in avoiding overtreatment and further
increases survival rates in patients undergoing cytoreductive surgery (CRS) and …

In a number of types of cancer, anoikis, a form of apoptosis induced by loss of extracellular
matrix (ECM) attachment, is disturbed. Anoikis resistance is essential in the formation of …